NEW YORK (GenomeWeb) – BioMérieux said today that its third quarter revenues increased 16 percent on a reported basis year over year driven in part by a 60 percent spike in molecular biology sales.
For the three months ended Sept. 30, the Marcy L'Etoile, France-based in vitro diagnostics firm reported revenues of €478.3 million ($532.8 million) compared to €412 million in Q3 2014.
On an organic basis and at constant exchange rates, Q3 revenues grew 9 percent year over year.
Clinical applications revenues rose 15 percent to €374.3 million from €325.3 million on a reported basis, while industrial applications grew 8 percent to €87.5 million from €81 million.
Within clinical applications, the firm's third quarter molecular biology sales increased 60 percent year over year to €50.2 million from €31.4 million. This included €30 million in sales from BioFire Diagnostics products, the company noted.
Also within clinical applications, sales for the microbiology segment, which includes the firm's Vitek mass spectrometry platforms and blood culture products, rose 8 percent year over year to €216.2 million from €199.3 million. Meantime, immunoassays, including the VIDAS 3 immunoanalyzer, grew 16 percent to €105.7 million from €91.3 million.
In industrial applications, Q3 sales grew 8 percent on a reported basis to €87.5 million from €81 million. This included the company's BioTheranostics unit, where sales more than doubled to €5.1 million from €2.5 million, and BioFire Defense, which saw its revenues grow more than fourfold to €9.1 million from €2.1 million in the year-ago period.
For the first nine months of 2015, BioMérieux's revenues grew 18 percent on a reported basis to €1.41 billion from €1.19 billion for the first nine months of 2014. On an organic basis and at constant exchange rates, revenues for the first nine months increased 8 percent.
BioMérieux said that molecular biology sales in the first nine months totaled €158.1 million, a 77 percent increase over €89.1 million in the first nine months of 2014. This included €97 million in sales from BioFire Diagnostics – approximately double the sales of BioFire Diagnostics products compared to the first nine months of 2014.
Based on the sales performance for the first nine months of the year, and assuming a flu epidemic of average intensity, BioMérieux raised its full-year organic growth objective to about 6.5 percent from a previous range of 4.5 percent to 6.5 percent.